Dysbiosis patterns during re-induction/salvage versus induction chemotherapy for acute leukemiaOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study asked whether gut dysbiosis patterns differ between first induction chemotherapy and repeat therapy in acute leukemia. Repeat therapy means re-induction or salvage for persistent or relapsed disease. Researchers analyzed thrice-weekly stool samples by 16S ribosomal RNA sequencing of the V4 region. They used mixed-effects models adjusting for antibiotics, feeding, disease, and week, plus SourceTracker to measure how far communities drifted from each patient's pre-chemotherapy baseline.
Who was studied?
The cohort was 20 adults with acute leukemia undergoing intensive inpatient chemotherapy at a Minnesota center. Thirteen received first induction and 7 received repeat therapy. Sixteen patients had acute myeloid leukemia and four had acute lymphoblastic leukemia. They provided 207 stool samples in total (133 induction, 74 repeat). The median time since prior intensive chemotherapy in the repeat group was 200 days. Antibiotic exposure was heavy across both groups.
What were the most important findings?
Repeat therapy independently predicted Enterococcus expansion (P = 0.006), controlling for antibiotics, disease, feeding, and chemotherapy week. Enterococcus reached near-100% relative abundance in some samples. Bayesian SourceTracker analysis showed repeat therapy communities departed more from baseline in weeks 1 to 3 (P less than 0.05), indicating greater ecosystem instability. Parenteral nutrition (P = 0.004) and anti-anaerobic antibiotics also predicted Enterococcus expansion. Diversity fell sharply with time in both groups; the induction-vs-repeat diversity difference was not significant (P = 0.09).
What are the greatest implications of this study?
The findings suggest prior intensive chemotherapy leaves the gut ecosystem less stable, making it more vulnerable to Enterococcus outgrowth during later treatment. This matters because enterococcal blooms raise bloodstream infection risk. The authors propose testing microbiota restoration therapies at the end of induction or before starting repeat therapy. The sample was small and mixed across disease and regimen, so it could not evaluate clinical outcomes. Results need confirmation in larger, more uniform cohorts.